HRT could prove vital in the fight against Alzheimer's in women. As research has shown, starting the treatment within five years of menopause can reduce the risk of Alzheimer's by as much as 32%, with observational studies showing a 22% lower dementia risk for all HRT users. Timing, therefore, is crucial, with early intervention offering the best chance of protecting brain function.
It's is evident from the University of Cambridge's study that, at best, HRT fails to prevent the structural changes to the brain that leave women more vulnerable than men to cognitive decline. At its worst, it can exacerbate certain issues. This revelation makes lifestyle interventions even more critical as the only reliable defense against diseases like Alzheimer's later in life. More research is needed on the HRT variable.
There is a 48% chance that a partial reprogramming-based therapy will receive regulatory approval for treating Alzheimer’s disease before January 1, 2035, according to the Metaculus prediction community.
© 2026 Improve the News Foundation.
All rights reserved.
Version 6.18.0